Dermatology Company Announces First Patient Enrollment In Netherton Syndrome Trial
Azitra has announced the screening and upcoming enrollment of the first patient in the Phase 1b trial of ATR-12, targeting Netherton Syndrome.
Disclaimer: The content provided in this article is for informational purposes only and should not be considered as medical advice, endorsement, or a recommendation for any specific treatment or product. Readers are encouraged to consult healthcare professionals for any medical concerns or questions.
We are working endlessly to pr…